drugset / Trial / NCT00055263
A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purposes of this study are to: * Test the safety of DN-101 in patients with advanced malignancies * Understand how fast the body absorbs, processes, and eliminates DN-101 * Determine the highest dose of DN-101 that is well tolerated by cancer patients * Learn how fast the body absorbs, processes, and eliminates DN-101 compared to the approved product
Timeline
- Start
- 2002-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcitriol | Small molecule | — | Oral |